We the undersigned 23 organizations urge you to protect and, if possible, increase funding for domestic viral hepatitis programs at the Centers for Disease Control and Prevention (CDC). At a time when we have tools including vaccines and curative treatments that can help eliminate viral hepatitis in the United States, we express our grave concern with the President’s FY 2026 budget request that eliminates $43 million in dedicated funding for hepatitis prevention. Instead, it proposes a $300 million block grant to states that would also include STD and tuberculosis prevention.
23 patient groups letter to House Appropriations in support of additional FY26 hepatitis programs funding
We the undersigned 22 organizations urge you to protect and, if possible, increase funding for domestic viral hepatitis programs at the Centers for Disease Control and Prevention (CDC). At a time when we have tools including vaccines and curative treatments that can help eliminate viral hepatitis in the United States, we express our grave concern with the President’s FY 2026 budget request that eliminates $43 million in dedicated funding for hepatitis prevention. Instead, it proposes a $300 million block grant to states that would also include STD and tuberculosis prevention.
Senate testimony on FY26 appropriations for HIV and hepatitis
As a nation, we are able to advance efforts to end the HIV and viral hepatitis epidemics. We possess proven prevention tools, including pre-exposure prophylaxis medication (PrEP), and effective treatments. We urge you to continue your historically strong commitment and leverage this pivotal moment to support the nation’s public health by comprehensively addressing these chronic diseases. Increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis and allow us to continue to hold the promise of ending these epidemics.
Opposition to Massachusetts S.875 to Create a Prescription Drug Accountability Board
The HIV+Hepatitis Policy Institute remains committed to advancing policies that ensure access to affordable medications while fostering the development needed to fight HIV and hepatitis. We urge you to oppose S.875 and recommend exploring alternative approaches that directly address affordability without risking access or undermining medical advancements.
House testimony on FY26 appropriations for HIV and hepatitis programs
This testimony is in support of funding for the following initiatives, programs and divisions at the Department of Health and Human Services: Ending the HIV Epidemic Initiative—$395 million for the CDC Division of HIV/AIDS Prevention, $358.6 million for the HRSA Ryan White HIV/AIDS Program, $207.3 million for the HRSA Community Health Centers, and $52 million for the Indian Health Service; Ryan White HIV/AIDS Program—$3.024 billion; CDC Division of HIV Prevention—$822.7 million; CDC Division of Viral Hepatitis—$150 million; and the HHS Office of Infectious Disease and HIV/AIDS Policy—$20 million. The HIV+Hepatitis Policy Institute also supports maintaining and funding CDC’s Eliminating Opioid-Related Infectious Diseases Program and Division of School and Adolescent Health; the Minority HIV/AIDS Initiative; AIDS Research 2 at the NIH; the Title X Family Planning Program; the Teen Pregnancy Prevention Program; and the SAMHSA HIV Block Grant.